NASDAQ:COGT Cogent Biosciences Q3 2024 Earnings Report $39.44 +0.75 (+1.94%) Closing price 04:00 PM EasternExtended Trading$39.44 0.00 (-0.01%) As of 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Cogent Biosciences EPS ResultsActual EPS-$0.64Consensus EPS -$0.57Beat/MissMissed by -$0.07One Year Ago EPS-$0.64Cogent Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACogent Biosciences Announcement DetailsQuarterQ3 2024Date11/12/2024TimeBefore Market OpensConference Call DateTuesday, November 12, 2024Conference Call Time7:00AM ETUpcoming EarningsCogent Biosciences' Q2 2026 earnings is estimated for Tuesday, August 4, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 5, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cogent Biosciences Earnings HeadlinesCogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)June 30, 2026 | finance.yahoo.comCogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)June 30, 2026 | globenewswire.comThree companies about to leapfrog Nvidia [And transform the entire industry]Tech forecaster George Gilder - who identified Amazon when it was still just an online bookstore and predicted mobile computing years before the iPhone - has identified three companies he calls the 'Trillion Dollar Triangle.' One of them went public just weeks ago. Demand for its technology is already outpacing supply, with major AI players among its biggest customers. Gilder says this kind of supply crunch is the tell that a new technology is transitioning from possibility to inevitability.July 6 at 1:00 AM | Eagle Publishing (Ad)Is Cogent Biosciences (COGT) ’s New Cancer Drug 100 Times More Precise Than What’s Already on the Market?June 22, 2026 | insidermonkey.comCogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage LeverageJune 14, 2026 | seekingalpha.comCogent Biosciences, Inc. (COGT) Presents at European Hematology Association (EHA) 2026 Congress - SlideshowJune 13, 2026 | seekingalpha.comSee More Cogent Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cogent Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cogent Biosciences and other key companies, straight to your email. Email Address About Cogent BiosciencesCogent Biosciences (NASDAQ:COGT) is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments. The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors. Preclinical studies have demonstrated the candidate’s ability to deplete immunosuppressive macrophages within the tumor microenvironment, resulting in antitumor activity as a monotherapy and in combination with checkpoint inhibitors. Cogent continues to explore additional novel small molecules that can influence immune-regulatory pathways in oncology. Founded in 2016 and headquartered in Cambridge, Massachusetts, Cogent Biosciences completed its initial public offering in 2020 and maintains operations in key U.S. research hubs. The company leverages collaborative partnerships with academic institutions and contract research organizations to advance its pipeline efficiently. While most of its clinical programs are currently being evaluated in North America, Cogent is positioned to pursue international trial sites as it progresses through later-stage development. Under the leadership of President and Chief Executive Officer Daniel Welch, Cogent Biosciences is guided by a management team with deep experience in oncology drug development, translational research, and regulatory strategy. The company’s board and scientific advisory committees include experts in immuno-oncology and precision medicine, supporting its mission to bring novel targeted therapies to patients with unmet medical needs. View Cogent Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term InvestorsMarketBeat Week in Review – 06/29 - 07/03Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive WeaponVisa’s Open USD Push Puts Circle’s Stablecoin Moat Under PressureGeneral Mills Is a 5-Star Turnaround Play for Buy and Hold InvestorsCopper Stocks Are Getting a Bigger Spotlight as Gold’s Rally CracksNike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
